1st International and 10th National Iranian Conference on Bioinformatics
Home Accepted Papers
Investigation of IL-17RA editing sites in patients with severe COVID-19
Paper ID : 1223-ICB10
Authors:
Javad Behroozi *1, Mehrdad Nasrollahzadeh Sabet2, Mojtaba Yousefi zoshk3, Ebrahim Hazrati4, Peyman Aslani5, Reza Mosaed6
1Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
2Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
3Department of Pediatrics, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
4Department of Anesthesiology and Critical Care, Aja University of Medical Sciences, Tehran, Iran.
5Department of Parasitology and Mycology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
6Department of Clinical Pharmacy, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
Abstract:
Interleukin 17 (IL-17) family is highly multi-purpose pro-inflammatory cytokines critical for a variety of processes, including host defense and pathogenesis of inflammatory disease. Interleukin 17 receptors (IL-17R) consists of 5 members and despite these functions, regulating immune and inflammatory responses, are another role of IL-17R. The aim of this study was to investigate IL-17RA editing sites in patients with severe COVID-19. RNA-seq raw data related to 40 COVID-19 hospitalized patients and 10 healthy donors were retrieved from the publicly available Gene Expression Omnibus (GEO) database. Quality control, alignment and variant calling were performed using FastQC, Hisat2 and Freebayes tools, respectively. RNA-DNA differences were filtered to remove known SNPs and low quality SNVs. Additionally, several quality-aware filtering steps were employed to increase the accuracy of identifying true RNA editing sites. Finaly, statistical significance for differences between patients and healthy donors editing ratios was assessed by the T test. Our results showed difference in 7 A to G editing sites on the 3’UTR of IL-17RA gene between patients and healthy donors (P<0.05). These editing sites could affect microRNA target recognition and subsequently affect the expression profile of IL-17RA. RNA editing of IL-17RA significantly differ between hospitalized COVID-19 patients and heathy peoples and anti-IL-17RA therapy in COVID-19 should be considered.
Keywords:
RNA-sequencing; COVID-19; RNA editing; IL-17RA.
Status : Paper Accepted (Poster Presentation)